Innate Pharma S.A. (FR:IPH) has released an update.
Innate Pharma S.A. announced the progression of the NK cell engager SAR443579 / IPH6101, developed with Sanofi, to Phase 2 trials for treating blood cancers, including acute myeloid leukemia. The initiation of Phase 2 has triggered a €4m milestone payment to Innate from Sanofi. The company’s proprietary ANKET® platform is used to create this new class of cancer immunotherapies, aiming to provide innovative treatments for cancer patients with high unmet needs.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
